Welcome to our dedicated page for BIO-RAD LABORATORIES SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIO-RAD LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIO-RAD LABORATORIES's regulatory disclosures and financial reporting.
Rajat Mehta, listed as Executive Vice President, GBL Commercial Operations at Bio-Rad Laboratories (BIO), filed an initial Form 3 reporting the Section 16 beneficial-ownership status. The event date is 08/04/2025 and the form is signed 08/14/2025. The filing states no securities beneficially owned (0 shares) by the reporting person, with ownership shown as direct (D) where applicable.